Digital transformation is reshaping how Novo Nordisk Global Business Services (GBS) supports clinical research by integrating automation, artificial intelligence, and advanced workflows to enhance the speed and safety of clinical trials. John Dawber, Corporate Vice President and Managing Director, outlines how his team is addressing intricate challenges within this evolving landscape.
As automation accelerates patient safety monitoring and data review processes, research teams are increasingly able to focus on interpretation, strategic planning, and enhancing overall trial quality. With advancements in artificial intelligence and machine learning, new possibilities are emerging in patient recruitment, predictive outcomes, and the design of personalized treatments.
For those interested in understanding the innovations that are driving this significant change and the future of clinical research, Dawber offers insights into how GBS is fostering smarter and more impactful trials, where technology effectively collaborates with human expertise.
In related news, GBS invites readers to join a community of over two million industry professionals by subscribing to their newsletter, which promises the latest insights and analyses delivered directly to inboxes.
